fluorouracil + folinic acid + mitomycin C

This is a combination chemotherapy regimen consisting of three drugs—fluorouracil (5-FU), folinic acid (leucovorin), and mitomycin C. It is used primarily in the treatment of advanced or metastatic cancers, including colorectal cancer and gastric cancer, particularly in patients who have progressed after standard therapies[1][3][8]. - **Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and repair, as well as interfering with RNA processing. - **Folinic acid** enhances the binding of fluorouracil’s active metabolite to thymidylate synthase, increasing its cytotoxic effect[5]. - **Mitomycin C** is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and function. The combination exploits synergistic effects to increase anti-tumor activity against rapidly dividing cells. This regimen has been studied for use in heavily pretreated metastatic colorectal cancer patients and advanced gastric cancer[1][8].

Other names

MLF regimen